MNKD
MannKind Corporation
$3.38
+0.07
(+2.11%)
Mkt Cap
1.04B
Volume
4,604,149
52W Range
2.23-6.51
Sector
Healthcare
Beta
1.04
EPS (TTM)
-0.08
P/E Ratio
295.58
Revenue (TTM)
360.78M
Rev Growth (5Y)
+39.9%
EPS Growth (5Y)
-37.5%
AlphaVal · Fair Value
$7.80
Undervalued · Strong
56.7% below fair value
AlphaQuality · Grade · Gated
F
High-Growth Software
30.0 / 100 pillar composite (overridden)
Company Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 348.97M | 285.50M | 198.96M | 99.77M | 75.44M | 65.14M | 63.04M | 27.86M | 11.74M | 174.76M | 0 | 0 |
| Net Income | 5.86M | 27.59M | (11.94M) | (87.40M) | (80.93M) | (57.24M) | (51.90M) | (86.97M) | (117.33M) | 125.66M | (368.44M) | (198.38M) |
| EPS | 0.02 | 0.10 | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.37 | -4.54 | -2.57 |
| Free Cash Flow | 13.69M | 32.82M | (8.35M) | (88.29M) | (73.17M) | (32.91M) | (91.05M) | (38.09M) | (64.78M) | (79.23M) | N/A | N/A |
| FCF / Share | 0.04 | 0.12 | -0.03 | -0.34 | -0.29 | -0.15 | -0.47 | -0.26 | -0.62 | -0.86 | N/A | N/A |
| Operating CF | 18.25M | 42.51M | 34.09M | (80.70M) | (61.71M) | (28.13M) | (88.48M) | (37.73M) | (64.78M) | (78.09M) | N/A | N/A |
| Total Assets | 792.18M | 393.84M | 475.20M | 295.28M | 321.16M | 108.61M | 93.72M | 107.70M | 84.58M | 107.06M | N/A | N/A |
| Total Debt | 473.38M | 47.70M | 272.62M | 288.40M | 289.22M | 123.44M | 121.41M | 102.49M | 156.82M | 148.50M | N/A | N/A |
| Cash & Equiv | 74.88M | 46.34M | 238.48M | 69.77M | 124.18M | 67.00M | 29.91M | 71.16M | 43.95M | 22.89M | N/A | N/A |
| Book Value | (51.02M) | (78.82M) | (246.17M) | (250.54M) | (209.35M) | (180.42M) | (190.53M) | (175.08M) | (214.73M) | (183.59M) | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.17M | 111.95M | 82.13M | 76.53M | 78.35M | 76.78M | 70.08M | 72.39M | 66.26M | 58.47M | 51.25M | 48.61M |
| Net Income | (16.62M) | (15.95M) | 7.99M | 668,000 | 13.16M | 7.42M | 11.55M | (2.01M) | 10.63M | 1.40M | 1.72M | (5.26M) |
| EPS | -0.05 | -0.05 | 0.03 | 0.00 | 0.04 | 0.03 | 0.04 | -0.01 | 0.04 | 0.01 | 0.01 | -0.02 |
| Free Cash Flow | (7.52M) | (9.95M) | 22.36M | 7.83M | (6.71M) | 19.75M | 7.91M | 861,000 | 4.29M | 15.80M | (2.72M) | (14.27M) |
| FCF / Share | -0.02 | -0.03 | 0.07 | 0.03 | -0.02 | 0.07 | 0.03 | 0.00 | 0.02 | 0.06 | -0.01 | -0.05 |
| Operating CF | (5.64M) | (7.96M) | 23.49M | 8.95M | (6.38M) | 22.64M | 9.33M | 3.83M | 6.70M | 21.68M | 8.66M | 2.60M |
| Total Assets | 744.40M | 792.18M | 494.64M | 411.70M | 410.14M | 393.84M | 464.20M | 443.84M | 480.88M | 475.20M | 320.33M | 313.42M |
| Total Debt | 436.67M | 473.38M | 225.95M | 46.82M | 47.25M | 157.22M | 240.28M | 231.03M | 267.79M | 272.62M | 277.53M | 279.08M |
| Cash & Equiv | 52.83M | 74.88M | 127.39M | 57.01M | 47.31M | 46.34M | 62.37M | 96.64M | 193.27M | 238.48M | 83.02M | 86.18M |
| Book Value | (59.20M) | (51.02M) | (44.55M) | (55.04M) | (58.62M) | (78.82M) | (209.93M) | (225.78M) | (229.97M) | (246.17M) | (251.78M) | (260.49M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MNKD News
The $59B Quiet Shift Reshaping How Patients Access Care
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind: It's Complicated
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
MannKind Corporation (NASDAQ:MNKD) Short Interest Up 29.8% in March